Oncology

Researchers at the Thomas Jefferson University have developed an online decision-support tool called the Decision Counseling Program that can help for men diagnosed with localized, low-risk prostate cancer make treatment choices.

Pharmacy benefit managers (PBMs) and large employer organizations are taking measures to save healthcare costs in 2017, and for PBMs, formulary exclusions is a fool-proof tactic.

Nivolumab failed to perform better than chemotherapy in patients with squamous as well as non-squamous non-small cell lung cancer (NSCLC).

Scientists at the Sidney Kimmel Comprehensive Cancer Center have discovered that certain genes involved in metabolic processes are upregulated in patients with renal cell carcinoma (RCC) who are resistant to nivolumab.

Outpatient service charges are estimated to cause a 29.9% spike in healthcare premiums in 2017, much higher than the 14.3% projected for medications.

Foundation Medicine’s comprehensive genomic profiling (CGP) assay has been submitted by the company for FDA review as well as for a CMS review in parallel.

Results from the CheckMate 066 study found that the checkpoint inhibitor nivolumab performs well in improving patients' long-term quality of survival benefit in patients with advanced melanoma.

Adrenal gland tumors that are defined as being nonfunctional may not really be so, and the hormones that these tumors secrete could increase an individual’s risk of cardiometabolic irregularities, according to a new study.

World Lung Cancer Day is a grassroots effort conceived by a lung cancer survivor. Here are a few updates on ways to prevent the disease and manage treatment.

This week, the top stories in managed care included the release of Medicare's Star ratings for hospital quality, a new proposal from CMS to require bundled payments for cardiac care, and an FDA panel recommended approving a continuous glucose monitoring system for dosing insulin.

Sharing information of diagnosis and treatment decisions reassured women newly diagnosed with breast cancer of their health choices, according to a new study published in JAMA Oncology.

A new study has found that combining ipilimumab with local peripheral treatments such as radiotherapy or electrochemotherapy can significantly better survival in patients with melanoma.